The past decade has witnessed a revolution in cancer research, largely driven by advances in high-throughput sequencing, functional genomics, and computational technologies. The affordability and technological maturity of high-throughput data generation enable individual labs to test and validate their hypotheses using unbiased approaches and facilitate consortium efforts such as The Cancer Genome Atlas (TCGA), Therapeutically Application Research to Generate Effective Treatments (TARGET), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) to profile tens of thousands of tumors on multiple molecular levels. In parallel, faster and smarter computational tools run both locally and on the cloud are continuously developed to analyze cancer genomic and epigenomic data. These advances help make precision oncology a reality for some cancer patients.
